NCT00466258View on ClinicalTrials.gov

LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

May 31, 2009

Study Completion Date

November 30, 2009

Conditions
HIV InfectionsDiffuse Large B Cell Lymphoma
Interventions
DRUG

R-CHOP

"* Cyclophosphamide 750 mg/m2 i.v. day 1~* Adriamycin 50 mg/m2 i.v. day 1~* Vincristine 1,4 mg/m2 i.v. day 1~* Prednisone 100 mg i.v or oral. days 1-5."

DRUG

Highly active antiretroviral therapy

Combined antiretroviral treatment (TARGA) wich include at lest 3 drugs. The combination should be accepted as an initial or rescue treatment.

DRUG

Central nervous system (CNS) prophylaxis

methotrexate (12 mg) cytarabine (30 mg) hydrocortisone (20 mg)

DRUG

Prophylaxis of opportunistic infections and support treatment

Pegfilgrastim

Trial Locations (15)

Unknown

H. Son Llatzer, Palma de Mallorca

Germans Trias i Pujol, Badalona

H. Clínic i Provincial, Barcelona, Barcelona

H. Vall d'Hebron, Barcelona, Barcelona

Hospital del Mar, Barcelona

Hospital Sant Pau, Barcelona, Barcelona

ICO - Duran i Reynals, Hospitalet de Llobregat, Barcelona

Consorci Sanitari de Mataró, Mataró

H. Parc Taulí, Sabadell

Consorci Sanitari de Terrassa, Terrassa

ICO - Josep Trueta, Girona

H. Gregorio Marañón, Madrid

Hospital de Navarra, Pamplona

H. Joan XXIII, Tarragona

Hospital Universitario Dr. Peset, Valencia

All Listed Sponsors
lead

PETHEMA Foundation

OTHER

NCT00466258 - LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) | Biotech Hunter | Biotech Hunter